CGTX
Cognition Therapeutics, Inc.1.5200
-0.0800-5%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
134.18MP/E (TTM)
-Basic EPS (TTM)
-0.47Dividend Yield
0%Recent Filings
8-K
2025 results, DLB progress
Cognition Therapeutics reported 2025 net loss of $23.5M, down from $34.0M in 2024, with R&D expenses dropping to $37.2M amid trial completions; cash stands at $37M, funding through Q2 2027. SHIMMER Phase 2 showed zervimesine stabilizing DLB psychosis 102% versus placebo. Cash lasts to 2027. FDA Psychiatry meeting targets mid-2026 for registrational alignment.
10-K
FY2025 results
Cognition Therapeutics posted FY2025 net loss of $23.5M, improved from $34.0M in FY2024, fueled by $23.4M NIA grant income offsetting $47.8M opex. R&D spend fell to $37.2M from $41.7M as Phase 2 trials wrapped, yet cash burn moderated to $24.6M. Q4 saw START trial fully enrolled with topline due post-18 months; SHIMMER showed DLB benefits while MAGNIFY voluntarily ended. Cash hit $37.0M after $37M raised via equity, funding ops through Q2 2027. No debt or buybacks. Pivotal risk: clinical trials may fail.
8-K
Advances zervimesine for DLB psychosis
Cognition Therapeutics announced plans on March 2, 2026, to advance zervimesine into a registrational trial for dementia with Lewy bodies (DLB) psychosis, affecting up to 75% of patients, following FDA Type C meeting minutes and Phase 2 SHIMMER data showing 86% slowing of neuropsychiatric decline versus placebo. No approved treatments exist; traditional antipsychotics worsen motor function in DLB, but zervimesine spared it. FDA alignment meeting set for mid-2026. FDA may reject registrational path.
8-K
FDA Type C meeting completed
Cognition Therapeutics completed a productive Type C meeting with the FDA on January 21, 2026, reviewing Phase 2b study plans for zervimesine in mild-to-moderate dementia with Lewy bodies, a condition lacking approved therapies. The company discussed clinically meaningful endpoints. Meeting minutes arrive later this quarter. Regulatory dialogue advances amid trial uncertainties.
8-K
Launches $75M ATM with Jefferies
Cognition Therapeutics terminated its prior $40M ATM program with B. Riley and Cantor Fitzgerald, effective December 18, 2025, with $12.5M remaining unsold. Same day, it inked a fresh $75M ATM sales agreement with Jefferies, paying 3% commission on sales. New shelf ready. Upsizes funding firepower cleanly.
ACOG
Alpha Cognition Inc.
5.43+0.42
CING
Cingulate Inc.
3.87-0.28
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
COYA
Coya Therapeutics, Inc.
5.83-0.08
DSGN
Design Therapeutics, Inc.
9.62+0.50
GANX
Gain Therapeutics, Inc.
3.86-0.09
IGC
IGC Pharma, Inc.
0.34+0.00
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
SAVA
Cassava Sciences, Inc.
2.93+0.13
VYGR
Voyager Therapeutics, Inc.
4.42+0.06